Literature DB >> 19363258

Challenges associated with metal chelation therapy in Alzheimer's disease.

Muralidhar L Hegde1, P Bharathi, Anitha Suram, Chitra Venugopal, Ramya Jagannathan, Pankaj Poddar, Pullabhatla Srinivas, Kumar Sambamurti, Kosagisharaf Jagannatha Rao, Janez Scancar, Luigi Messori, Luigi Zecca, Paolo Zatta.   

Abstract

A close association between brain metal dishomeostasis and the onset and/or progression of Alzheimer's disease (AD) has been clearly established in a number of studies, although the underlying biochemical mechanisms remain obscure. This observation renders chelation therapy an attractive pharmacological option for the treatment of this disease. However, a number of requirements must be fulfilled in order to adapt chelation therapy to AD so that the term "metal targeted strategies" seems now more appropriate. Indeed, brain metal redistribution rather than brain metal scavenging and removal is the major goal of this type of intervention. The most recent developments in metal targeted strategies for AD will be discussed using, as useful examples, clioquinol, curcumin, and epigallocatechin, and the future perspectives will also be outlined.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19363258      PMCID: PMC2931820          DOI: 10.3233/JAD-2009-1068

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  91 in total

Review 1.  Chemical and biological considerations in the treatment of metal intoxications by chelating agents.

Authors:  Ole Andersen
Journal:  Mini Rev Med Chem       Date:  2004-01       Impact factor: 3.862

Review 2.  Aluminium in Alzheimer's disease: are we still at a crossroad?

Authors:  Veer Bala Gupta; S Anitha; M L Hegde; L Zecca; R M Garruto; R Ravid; S K Shankar; R Stein; P Shanmugavelu; K S Jagannatha Rao
Journal:  Cell Mol Life Sci       Date:  2005-01       Impact factor: 9.261

3.  Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease.

Authors:  L Reznichenko; T Amit; H Zheng; Y Avramovich-Tirosh; M B H Youdim; O Weinreb; S Mandel
Journal:  J Neurochem       Date:  2006-03-15       Impact factor: 5.372

4.  Testing the mettle of PBT2 for Alzheimer's disease.

Authors:  Norman R Relkin
Journal:  Lancet Neurol       Date:  2008-07-30       Impact factor: 44.182

5.  Relative efficacy of chelating agents on excretion and tissue distribution of manganese in mice.

Authors:  D J Sánchez; M Gómez; J L Domingo; J M Llobet; J Corbella
Journal:  J Appl Toxicol       Date:  1995 Jul-Aug       Impact factor: 3.446

6.  Desferrioxamine and Alzheimer's disease: video home behavior assessment of clinical course and measures of brain aluminum.

Authors:  D R McLachlan; W L Smith; T P Kruck
Journal:  Ther Drug Monit       Date:  1993-12       Impact factor: 3.681

Review 7.  Nanoparticle and other metal chelation therapeutics in Alzheimer disease.

Authors:  Gang Liu; Matthew R Garrett; Ping Men; Xiongwei Zhu; George Perry; Mark A Smith
Journal:  Biochim Biophys Acta       Date:  2005-09-25

8.  Curcuminoids, curcumin, and demethoxycurcumin reduce lead-induced memory deficits in male Wistar rats.

Authors:  Amichand Dairam; Janice L Limson; Gareth M Watkins; Edith Antunes; Santy Daya
Journal:  J Agric Food Chem       Date:  2007-02-07       Impact factor: 5.279

Review 9.  Metals, toxicity and oxidative stress.

Authors:  M Valko; H Morris; M T D Cronin
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

10.  Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron- chelating- antioxidants, M-30 and green tea polyphenol, EGCG.

Authors:  Yael Avramovich-Tirosh; Lydia Reznichenko; Tamar Mit; Hailin Zheng; Mati Fridkin; Orly Weinreb; Silvia Mandel; Moussa B H Youdim
Journal:  Curr Alzheimer Res       Date:  2007-09       Impact factor: 3.498

View more
  35 in total

Review 1.  Neuronutrition and Alzheimer's disease.

Authors:  Balenahalli N Ramesh; T S Sathyanarayana Rao; Annamalai Prakasam; Kumar Sambamurti; K S Jagannatha Rao
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 2.  Oxidative genome damage and its repair: implications in aging and neurodegenerative diseases.

Authors:  Muralidhar L Hegde; Anil K Mantha; Tapas K Hazra; Kishor K Bhakat; Sankar Mitra; Bartosz Szczesny
Journal:  Mech Ageing Dev       Date:  2012-01-31       Impact factor: 5.432

3.  Specific Inhibition of NEIL-initiated repair of oxidized base damage in human genome by copper and iron: potential etiological linkage to neurodegenerative diseases.

Authors:  Muralidhar L Hegde; Pavana M Hegde; Luis M F Holthauzen; Tapas K Hazra; K S Jagannatha Rao; Sankar Mitra
Journal:  J Biol Chem       Date:  2010-07-09       Impact factor: 5.157

Review 4.  The role of chelation in the treatment of other metal poisonings.

Authors:  Silas W Smith
Journal:  J Med Toxicol       Date:  2013-12

Review 5.  An overview on therapeutics attenuating amyloid β level in Alzheimer's disease: targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels.

Authors:  Xiaoling Zhou; Yifei Li; Xiaozhe Shi; Chun Ma
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

Review 6.  Oxidative genome damage and its repair in neurodegenerative diseases: function of transition metals as a double-edged sword.

Authors:  Muralidhar L Hegde; Pavana M Hegde; K S Rao; Sankar Mitra
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

Review 7.  Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer's disease from a ferroptosis perspective.

Authors:  Paul J Derry; Muralidhar L Hegde; George R Jackson; Rakez Kayed; James M Tour; Ah-Lim Tsai; Thomas A Kent
Journal:  Prog Neurobiol       Date:  2019-10-08       Impact factor: 11.685

Review 8.  Chronic oxidative damage together with genome repair deficiency in the neurons is a double whammy for neurodegeneration: Is damage response signaling a potential therapeutic target?

Authors:  Haibo Wang; Prakash Dharmalingam; Velmarini Vasquez; Joy Mitra; Istvan Boldogh; K S Rao; Thomas A Kent; Sankar Mitra; Muralidhar L Hegde
Journal:  Mech Ageing Dev       Date:  2016-09-20       Impact factor: 5.432

9.  The native copper- and zinc-binding protein metallothionein blocks copper-mediated Abeta aggregation and toxicity in rat cortical neurons.

Authors:  Roger S Chung; Claire Howells; Emma D Eaton; Lana Shabala; Kairit Zovo; Peep Palumaa; Rannar Sillard; Adele Woodhouse; William R Bennett; Shannon Ray; James C Vickers; Adrian K West
Journal:  PLoS One       Date:  2010-08-11       Impact factor: 3.240

Review 10.  Metal ion physiopathology in neurodegenerative disorders.

Authors:  Silvia Bolognin; Luigi Messori; Paolo Zatta
Journal:  Neuromolecular Med       Date:  2009-11-28       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.